Full Year 2024 Results Key Financial Results Revenue: US$30.8m (down 15% from ...

Operator Good day, and welcome to the Bionano fourth quarter 2024 earnings conference call. Today's conference is being ...

Discover Bionano Genomics' Q4 2024 earnings insights, focusing on operational efficiency, core customer utilization, and 2025 growth strategies with new ...

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook ...

Bionano Genomics Inc (BNGO) reports improved gross margins and reduced operating expenses, while facing revenue declines and ...

Cash, cash equivalents, and available-for-sale securities as of December 31, 2024 were $20.9M, of which $11.4M was subject to certain ...

Analysts estimate that Bionano Genomics will report an earnings per share (EPS) of $-8.40. The announcement from Bionano ...

Bionano Genomics reported a 24% year-over-year revenue decline for Q4 2024, totaling $8.2 million, alongside a modest full-year product revenue increase. The company’s stock saw a 3.79% decline ...

Q4 2024 Earnings Call Transcript March 31, 2025 Bionano Genomics, Inc. reports earnings inline with expectations. Reported ...

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025.

Good day, and welcome to the Bionano fourth quarter 2024 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to David Holmes from ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bionano Genomics wasn’t one of them. The 10 stocks that made ...